PFBT
GLUE icon

Parkside Financial Bank & Trust’s Monte Rosa Therapeutics GLUE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-95
Closed -$441 – 2845
2025
Q1 		$441 Buy
+95
New +$583 ﹤0.01% 2483

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parkside Financial Bank & Trust's GLUE Position: Q2 2025 in Review

Parkside Financial Bank & Trust sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 95 shares — an estimated $441 sold.

Parkside Financial Bank & Trust first reported a position in GLUE in Q1 2025 and held it in 1 quarter. The position peaked at $441 in Q1 2025. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Parkside Financial Bank & Trust reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 95 Monte Rosa Therapeutics shares in Q2 2025, an estimated $441.
  • Parkside Financial Bank & Trust first reported a position in Monte Rosa Therapeutics in Q1 2025 and held it in 1 quarter.
  • Parkside Financial Bank & Trust's Monte Rosa Therapeutics position peaked at $441 in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2025, filed 7 Aug 2025.